318 related articles for article (PubMed ID: 19186237)
1. Multidisciplinary treatment of gastrointestinal stromal tumors.
Kingham TP; DeMatteo RP
Surg Clin North Am; 2009 Feb; 89(1):217-33, x. PubMed ID: 19186237
[TBL] [Abstract][Full Text] [Related]
2. [Consensus on the medical treatment of gastrointestinal stromal tumors].
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
[No Abstract] [Full Text] [Related]
3. Molecular research directions in the management of gastrointestinal stromal tumors.
Tarn C; Godwin AK
Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
[TBL] [Abstract][Full Text] [Related]
4. Imatinib treatment for gastrointestinal stromal tumour (GIST).
Lopes LF; Bacchi CE
J Cell Mol Med; 2010 Jan; 14(1-2):42-50. PubMed ID: 19968734
[TBL] [Abstract][Full Text] [Related]
5. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal stromal tumor and its targeted therapeutics.
Dupart J; Zhang W; Trent JC
Chin J Cancer; 2011 May; 30(5):303-14. PubMed ID: 21527063
[TBL] [Abstract][Full Text] [Related]
7. Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case.
Utsunomiya T; Okamoto M; Yano S; Kameyama T; Matsuyama A; Kuma S; Yamamoto M; Fujiwara M; Ishida T
Surg Today; 2008; 38(1):65-7. PubMed ID: 18085368
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal stromal tumors: imatinib and beyond.
Schnadig ID; Blanke CD
Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
[TBL] [Abstract][Full Text] [Related]
9. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
[TBL] [Abstract][Full Text] [Related]
10. Emergence of imatinib resistance associated with downregulation of c-kit expression in recurrent gastrointestinal stromal tumor (GIST): optimal timing of resection.
Dudeja V; Armstrong LH; Gupta P; Ansel H; Askari S; Al-Refaie WB
J Gastrointest Surg; 2010 Mar; 14(3):557-61. PubMed ID: 20033343
[TBL] [Abstract][Full Text] [Related]
11. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
Zheng S; Jia J; Pan YL; Tao DY; Lu HS
Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
[No Abstract] [Full Text] [Related]
12. [KIT mutation analysis in pathological diagnosis and target-therapy of gastrointestinal stromal tumors: an update].
Chen LR
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):440-3. PubMed ID: 17845754
[No Abstract] [Full Text] [Related]
13. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor.
Kleinbaum EP; Lazar AJ; Tamborini E; Mcauliffe JC; Sylvestre PB; Sunnenberg TD; Strong L; Chen LL; Choi H; Benjamin RS; Zhang W; Trent JC
Int J Cancer; 2008 Feb; 122(3):711-8. PubMed ID: 17943734
[TBL] [Abstract][Full Text] [Related]
14. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
15. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
[TBL] [Abstract][Full Text] [Related]
16. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y
Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561
[TBL] [Abstract][Full Text] [Related]
17. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.
Yeh CN; Chen TW; Tseng JH; Liu YY; Wang SY; Tsai CY; Chiang KC; Hwang TL; Jan YY; Chen MF
J Surg Oncol; 2010 Nov; 102(6):599-603. PubMed ID: 20976730
[TBL] [Abstract][Full Text] [Related]
18. [GIST: adjuvant treatment in Austria].
Brodowicz T; Kühr T
Wien Med Wochenschr; 2009; 159(15-16):399-402. PubMed ID: 19696984
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.
Yeh CN; Chen TW; Wu TJ; Hsueh S; Jan YY
World J Gastroenterol; 2006 Jun; 12(23):3760-5. PubMed ID: 16773696
[TBL] [Abstract][Full Text] [Related]
20. Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment.
Koyama T; Nimura H; Kobayashi K; Marushima H; Odaira H; Kashimura H; Mitsumori N; Yanaga K
Gastric Cancer; 2006; 9(3):235-9. PubMed ID: 16952044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
